Antiretroviral drugs toxicity and immune status of HIV patients under comprehensive care in Embu, Kenya

dc.contributor.authorGicheru, M. M.
dc.contributor.authorNamu, John Samuel
dc.contributor.authorNg'ang'a, Z.
dc.date.accessioned2014-07-02T12:47:18Z
dc.date.available2014-07-02T12:47:18Z
dc.date.issued2013-02
dc.description.abstractThe objective of this study was to determine toxicity and immune status of HIV patients under ARVs (Zidovudine, Stavudine and Nevirapine) which comprises first line ARV combination regime currently being used in Kenya. A total of sixty (60) HIV patients participated in the study after consenting to undergo comprehensive care. A control group of forty (40) HIV patients on only contrimoxale (septrin), Analysis of Variance (ANOVA), t-test and correlation coeficientwere used to analyse the data. The results showed treatment with ARVs may cause. Based on the findings of this study it is recommended that the ARV drug combination used may be initiated for patients at baseline CD4 counts of 101-150 cells/μl of blood. However change to another ARV drug combination regime may be introduced after three months of use to minimize toxicity associated with prolonged use.en_US
dc.identifier.citationEuropean International Journal of Science and Technology Vol. 2 No.1 February 2013en_US
dc.identifier.issn2304-9693
dc.identifier.urihttp://www.cekinfo.org.uk/images/frontImages/gallery/Vol._2_No._1_/7.pdf
dc.identifier.urihttp://ir-library.ku.ac.ke/handle/123456789/10277
dc.language.isoenen_US
dc.subjectAntiretroviralsen_US
dc.subjectToxicityen_US
dc.subjectmmune statusen_US
dc.subjectCreatinineen_US
dc.titleAntiretroviral drugs toxicity and immune status of HIV patients under comprehensive care in Embu, Kenyaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Antiretroviral drugs toxicity....pdf
Size:
50.96 KB
Format:
Adobe Portable Document Format
Description:
abstract
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: